Amgen Earnings Call Transcripts
Fiscal Year 2026
-
Strong double-digit growth in 2025 was driven by six key product portfolios, with major contributions from rare disease, biosimilars, and innovative oncology. The pipeline is robust, highlighted by MariTide's differentiated dosing and multiple phase III programs, while disciplined M&A and operational execution support long-term growth.
-
Strong double-digit growth in 2025 was driven by key products and expanding portfolios in rare disease, oncology, and biosimilars. Pipeline innovation and disciplined data generation underpin long-term growth, while integrated access strategies and manufacturing efficiency support profitability amid pricing pressures.
-
The summit highlighted a focus on transformative oncology therapies, with major advances in T-cell engagers, precision small molecules, and AI-driven discovery. Key products like IMDELLTRA, LUMAKRAS, and BLINCYTO are expanding indications, while new assets and technologies are being selectively developed.
-
Multiple late-stage clinical programs are advancing, including new phase III trials for UPLIZNA and daxdilimab, and label expansion for TEZSPIRE. TEZSPIRE's upstream TSLP targeting and inhaled TSLP agents are positioned for growth, with key data readouts expected later this year.
-
Strong 2025 results were driven by blockbuster products, new FDA approvals, and robust biosimilars growth. The 2026 outlook centers on under-penetrated therapies, a deep late-stage pipeline, and strategic investments in innovation and manufacturing.
Fiscal Year 2025
-
Double-digit revenue and EPS growth in 2025 was driven by strong performance across core brands, with Repatha, Evenity, Tezspire, and biosimilars leading gains. 2026 guidance anticipates continued growth despite biosimilar competition, supported by robust pipeline and disciplined capital allocation.
-
Strong volume-driven growth and robust R&D investment are fueling momentum across six major product drivers, with significant advances in rare disease, oncology, and cardiometabolic pipelines. Strategic capital allocation and innovative access models support long-term expansion.
-
Strong revenue and volume growth driven by six key product areas, robust pipeline progress, and strategic capital allocation were highlighted. Repatha, TEZSPIRE, and the rare disease portfolio showed significant momentum, while new data and launches are expected to sustain growth into 2026 and beyond.
-
Q3 2025 saw 12% revenue growth to $9.6B, driven by strong volume and double-digit product gains across all segments. Raised 2025 guidance, highlighted major clinical milestones, and advanced pipeline assets in obesity, cardiovascular, and oncology.
-
Strong Q2 growth was driven by key products and a robust pipeline, with major investments in U.S. manufacturing and innovation. The company is advancing multiple late-stage programs, managing biosimilar competition, and maintaining disciplined capital allocation while engaging on policy reforms and global pricing.
-
Strong Q2 results were driven by double-digit growth across key products and therapeutic areas, with significant pipeline progress in obesity, cardiovascular, oncology, and rare diseases. Strategic expansion, disciplined capital allocation, and innovation position the business for sustained growth.
-
Q2 2025 saw 9% revenue growth and 13% volume increase, with 15 products achieving double-digit sales growth. Strong performance across general medicine, rare disease, inflammation, oncology, and biosimilars, alongside robust pipeline progress and continued investment in innovation.
-
MariTide achieved up to 20% weight loss at 52 weeks with strong cardiometabolic benefits and a favorable safety profile, especially with optimized dose escalation. Phase III studies are underway with robust enrollment, targeting broad indications and flexible dosing.
-
Strong Q1 growth driven by double-digit gains across key products and robust pipeline progress. Major investments in manufacturing and innovation support expansion, while upcoming data readouts for MariTide, Repatha, and Olpasiran are expected. Focus remains on execution, policy engagement, and capital allocation to innovation.
-
Strong commercial momentum continues with double-digit growth across key products and biosimilars. The pipeline advances with MariTide and olpasiran, while upcoming data at ADA and multiple regulatory milestones are expected to drive further growth.
-
Strong Q1 growth was driven by double-digit gains across key products and biosimilars, with major pipeline progress in obesity, rare disease, and oncology. Enhanced access strategies and a robust manufacturing footprint support expansion, while upcoming data and regulatory milestones are expected to further strengthen the portfolio.
-
Strong Q1 growth was driven by double-digit gains across key products and a robust biosimilars portfolio. Major pipeline assets in obesity and cardiovascular disease are advancing, with significant R&D investment and strategic US manufacturing expansion supporting long-term growth.
-
Q1 2025 saw 9% revenue growth and strong double-digit sales across key products, with robust performance in general medicine, rare disease, inflammation, oncology, and biosimilars. Guidance for 2025 was reaffirmed, and significant R&D and regulatory milestones were achieved.
-
Strong 2024 momentum was highlighted by double-digit product growth, major pipeline advances, and robust biosimilar sales. Key updates included the initiation of phase III MariTide trials, significant manufacturing investments, and new product launches, with multiple late-stage readouts expected in 2025.
-
The summit highlighted a robust oncology pipeline with nine Phase III trials across five assets, focusing on T-cell engagers and precision oncology. Key assets like BLINCYTO, Imdelltra, and xaluritamig are advancing into earlier treatment lines, with new formulations and indications under study.
-
Strong revenue growth was driven by portfolio breadth and the Horizon acquisition, with robust momentum into 2025. Key pipeline advances include Olpasiran for cardiovascular risk and MariTide for obesity, both showing promising efficacy. Major oncology and respiratory readouts are expected this year.
-
Strong growth is expected through 2030, driven by blockbuster inline products, a robust pipeline (notably MariTide for obesity), and global biosimilars leadership. Key priorities include international expansion, new indications, and disciplined investment in innovation.
Fiscal Year 2024
-
Delivered 19% revenue growth in 2024, driven by double-digit gains across key products and strong global execution. 2025 guidance projects continued growth, with investments in innovation, pipeline expansion, and international launches expected to offset price pressures and patent expiries.
-
Strong Q3 growth driven by diverse portfolio and major advances in obesity, rare disease, and oncology. MariTide shows ~20% weight loss at 52 weeks, with flexible dosing and robust patient interest. $1B manufacturing investment and pipeline innovation position for future expansion.
-
Strong Q3 growth was driven by double-digit product gains and robust performance across oncology, rare disease, inflammation, and general medicine. MariTide showed promising phase II results in obesity, with improved tolerability and flexible dosing under study. R&D and commercial strategies emphasize innovation, global reach, and operational discipline.
-
MariTide's phase II results show up to 20% weight loss at 52 weeks without plateau, robust cardiometabolic improvements, and strong tolerability with dose escalation. Monthly or less frequent dosing is effective, and over 90% of patients continued into year two.
-
Strong growth across rare disease, general medicine, and oncology portfolios, with significant R&D investment and volume-driven revenue gains. Confidence in MariTide's potential for obesity and diabetes remains high, with phase II data expected by year-end. Pipeline expansion in immunology and oncology continues, supported by robust trial designs and capital allocation focused on innovation.
-
Q3 revenues rose 23% to $8.5B, driven by double-digit growth in key products and strong performance across all therapeutic areas. Pipeline progress, Horizon integration, and biosimilar launches support a positive outlook, with 2024 revenue guidance of $33.0–$33.8B.
-
Rocatinlimab met all primary and key secondary endpoints in Phase 3 atopic dermatitis, showing significant efficacy and a favorable safety profile. Uplizna demonstrated strong results in both generalized myasthenia gravis and IgG4-related disease, with rapid, durable efficacy and no new safety signals.
-
Leaders highlighted robust growth, a maturing and de-risked pipeline, and strategic investments in R&D and manufacturing. Key milestones include approvals and data readouts across oncology, rare disease, and cardiometabolic programs, with major launches and global expansion planned.
-
Strong growth in core franchises and international markets is supported by innovation in general medicine, oncology, inflammation, and rare disease. The pipeline features next-gen assets like MariTide and Olpasiran, while policy changes and AI investments shape strategy.
-
Q2 2024 saw record revenue of $8.4B, up 20% year-over-year, with strong double-digit growth across key products and regions. The pipeline advanced with new approvals and positive data, while guidance for 2024 was raised and Horizon integration progressed well.
-
A transformative period is underway, with robust growth across four therapeutic pillars and a strong late-stage pipeline. Key assets like MariTide, IMDELLTRA, and TEZSPIRE are advancing, supported by expanded manufacturing and disciplined capital allocation.
-
Management highlighted strong confidence in MariTide's differentiated profile and manufacturing readiness, with a broad phase 3 program planned for obesity and related conditions. The pipeline is advancing across oncology, rare disease, and immunology, with multiple product launches and readouts expected in 2024.